BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  HanAll Biopharma Reports Second Quarter 2022 Results and Provides Business Update

  HanAll Biopharma (KRX: 009420.KS), a global biopharmaceutical company focusing on delivering breakthrough therapies for patients, reported financial results for the second quarter 2022 as well as an update to its R&D progress.

  July 29, 2022

   · 

  7 min read
• Business

  Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights

  Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Friday, August 5, 2022 to report financial results for the quarter ended June 30, 2022 and discuss recent corporate highlights.

  July 29, 2022

   · 

  1 min read
• Pharm Country

  Sen-Jam Pharmaceutical, The World’s Most Resourceful Drug Innovator, Turns To Crowdfunding To Secure Financing To Advance Critical Therapeutics

  Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy, started and will be completing this weekend, a Community Fundraising effort to drive drug development.

  July 29, 2022

   · 

  3 min read
• Deals

  VolitionRx Limited Announces Pricing of $6 Million Underwritten Public Offering of Common Stock

  VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share.

  July 29, 2022

   · 

  5 min read
• FDA

  FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

  Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

  July 29, 2022

   · 

  6 min read
• BioMidwest

  Fresenius Kabi Announces U.S. Availability of Cancer Therapeutic Thiotepa

  Fresenius Kabi announced today it has introduced Thiotepa for Injection, USP, in the United States.

  July 29, 2022

   · 

  3 min read
• BioMidwest

  Cosmos Holdings Announces Name Change to Cosmos Health, Reflecting Company’s Evolution into an Innovative Global Healthcare Group, Driven by One Purpose: Improving People’s Lives

  Cosmos Holdings, Inc. (“the Company”) (NASDAQ:COSM) announced today that it is changing the name of the Company to Cosmos Healthto better reflect the Company’s evolution into an innovative global healthcare group with a focus on improving people’s lives.

  July 29, 2022

   · 

  4 min read
• Business

  IRADIMED CORPORATION Announces Second Quarter 2022 Financial Results

  IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three and six months ended June 30, 2022.

  July 29, 2022

   · 

  10 min read
• Type 2 Diabetes Treatment Market Insights: Competitive Scenario of the Industry with Growth Prospect 2030

  Forecast to 2030,’ thoroughly examines the Type 2 Diabetes Treatment industry to provide essential data & information for the targeted readers.

  July 29, 2022

   · 

  6 min read
• Scoliosis Treatment Market Research Report on Future Trends, Growth Opportunities and Industry Statistics Till 2030

  Forecast to 2030,’ thoroughly examines the Scoliosis Treatment industry to provide essential data & information for the targeted readers.

  July 29, 2022

   · 

  5 min read